Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

Heart

Volumn 90, Issue 7, 2004, Pages 765-770

  Macdonald, J E ^a   Kennedy, N ^a   Struthers, A D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; QT INTERVAL; VASCULARIZATION;

EID: 3042693878     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.017368     Document Type: Article

References (39)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
2. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with LV dysfunction after MI. N Engl J Med 2003;384:1309-21.
3. Struthers AD. Effect of aldosterone on the vascular bed: introducing aldosterone induced vasculopathy. In Braunwald E, ed. Harrison's advances in cardiology. New York: McGraw Hill, 2003:12-7.
4. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
5. Farquharson C, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in man: evidence for an aldosterone induced vasculopathy. Clin Sci 2002;103:425-31.
6. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
7. Rocha R, Chander PHN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension 1998;31:451-8.
8. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
9. Kinugawa T, Ogino K, Kato M, et al. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. Gen Pharmacol 1998;31:93-9.
10. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
11. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
12. Zannad F, Alla F, Dousset B, on behalf of RALES Investigators, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000;102:2700-6.
13. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10.
14. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-7.
15. Farquharson C, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-6.
16. Landmesser U, Drexler H. Allopurinol and endothelial function in heart failure. Circulation 2002;106:173-5.
17. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995;25:918-23.
18. Molgaard H. Evaluation of the Reynolds Pathfinder II system for 24 h heart rate variability analysis. Eur Heart J 1991;12:1153-62.
19. Anon. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-65.
20. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106-7.
21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
22. Gokce N, Keaney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
23. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
24. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-10.
25. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
26. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;10:1899-906.
27. Al Suwaidi J, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
28. Halcox JPJ, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
29. Nakamura M, Funakoshi T, Arakawa N, et al. Effect of ACE inhibitors on endothelium dependent peripheral vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1321-7.
30. Vita JA, Keaney JF. Endothelial function: a barometer of cardiovascular risk. Circulation 2002;106:640-2.
31. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
32. Sun Y, Ratajska A, Zhou G, et al. ACE and myocardial fibrosis in the rat receiving AII or aldosterone. J Lab Clin Med 1993;122:395-403.
33. 1 receptor sub-type as a cardiac target of aldosterone: role in aldosterone salt induced fibrosis. Hypertension 1999;33:981-6.
34. Forquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-75.
35. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma N-BNP levels improves outcome. Lancet 2000;355:1126-30.
36. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.
37. Wong KYK, MacWalter RS, Douglas D, et al. Long QTc predicts future cardiac death in stroke survivors. Heart 2003;89:377-89.
38. Schepkens H, Vanholder R, Billiouwv JM, et al. Life threatening hyperkalaemia during combined therapy with ACE inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41.
39. Berry C, McMurray JJV. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:e8.